Details of the Drug

General Information of Drug (ID: DMP9HBO)

Drug Name

Sucralfate

Synonyms

SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1], [2], [3]

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
4

Molecular Weight

1577.9

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 20 hours [4]

Chemical Identifiers

Formula: C12H54Al9O55S8
Canonical SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
InChI: InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
InChIKey: YZPQNHUVIVIUCT-JTJNLBSYSA-F

Cross-matching ID

PubChem CID: 121494085
CAS Number: 54182-58-0
DrugBank ID: DB00364
TTD ID: D06ULU
ACDINA ID: D00641

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Modulator	[5], [2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acne vulgaris

ICD Disease Classification

ED80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Fibroblast growth factor-2 (FGF2)	DTT	FGF2	6.36E-03	0.05	0.3

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sucralfate

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sarecycline	DMLZNIQ	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Sarecycline .	Acne vulgaris [ED80]	[14]
-----------

Coadministration of a Drug Treating the Disease Different from Sucralfate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Promazine	DMZAL7W	Minor	Decreased absorption of Sucralfate due to adsorption of Promazine.	Appearance/behaviour symptom [MB23]	[15]
Ofloxacin	DM0VQN3	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[16]
Trovafloxacin	DM6AN32	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Gemifloxacin	DMHT34O	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Norfloxacin	DMIZ6W2	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[16]
Omadacycline	DMR2J95	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Omadacycline.	Bacterial infection [1A00-1C4Z]	[14]
Levofloxacin	DMS60RB	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Minocycline	DMVN5OH	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Minocycline.	Bacterial infection [1A00-1C4Z]	[14]
Lomefloxacin	DMVRH9C	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Tetracycline	DMZA017	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Tetracycline.	Bacterial infection [1A00-1C4Z]	[14]
Risedronate	DM5FLTY	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Risedronate.	Bone paget disease [FB85]	[17]
Alendronate	DMY2KX9	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Alendronate.	Bone paget disease [FB85]	[17]
Grepafloxacin	DMGLX0T	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Grepafloxacin.	Bronchitis [CA20]	[16]
Sotalol	DML60TN	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Sotalol.	Cardiac arrhythmia [BC9Z]	[18]
Chenodiol	DMQ8JIK	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Chenodiol.	Cholelithiasis [DC11]	[19]
Doxercalciferol	DM6FG1P	Major	Altered absorption of Sucralfate caused by Doxercalciferol.	Chronic kidney disease [GB61]	[20]
Mephenytoin	DM5UGDK	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[21]
Timolol	DM3NXRU	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Timolol.	Essential hypertension [BA00]	[18]
Nadolol	DMW6GVL	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Nadolol.	Essential hypertension [BA00]	[18]
Ketoconazole	DMPZI3Q	Minor	Altered absorption of Sucralfate caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[22]
Carteolol	DMFMDOB	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Carteolol.	Glaucoma [9C61]	[18]
Carvedilol	DMHTEAO	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Carvedilol.	Heart failure [BD10-BD1Z]	[18]
Furosemide	DMMQ8ZG	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Furosemide.	Heart failure [BD10-BD1Z]	[20]
Digoxin	DMQCTIH	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Digoxin.	Heart failure [BD10-BD1Z]	[21]
Digitoxin	DMWVIGP	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Digitoxin.	Heart failure [BD10-BD1Z]	[21]
Isoniazid	DM5JVS3	Minor	Altered absorption of Sucralfate caused by Isoniazid.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Dolutegravir	DMCZGRE	Major	Decreased absorption of Sucralfate due to formation of complexes caused by Dolutegravir.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Paricalcitol	DMYBV3G	Major	Altered absorption of Sucralfate caused by Paricalcitol.	Hyper-parathyroidism [5A51]	[20]
Acebutolol	DM0TI4U	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Acebutolol.	Hypertension [BA00-BA04]	[18]
Bisoprolol	DM3UZ95	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Bisoprolol.	Hypertension [BA00-BA04]	[18]
Penbutolol	DM4ES8F	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Penbutolol.	Hypertension [BA00-BA04]	[18]
Nebivolol	DM7F1PA	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Nebivolol.	Hypertension [BA00-BA04]	[18]
Pindolol	DMD2NV7	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Pindolol.	Hypertension [BA00-BA04]	[18]
Labetalol	DMK8U72	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Labetalol.	Hypertension [BA00-BA04]	[18]
Quinapril	DMR8H31	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Quinapril.	Hypertension [BA00-BA04]	[20]
Levothyroxine	DMHN027	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Levothyroxine.	Hypo-thyroidism [5A00]	[25]
Allopurinol	DMLPAOB	Moderate	Altered absorption of Sucralfate caused by Allopurinol.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[26]
Baloxavir marboxil	DM1UV7F	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Baloxavir marboxil.	Influenza [1E30-1E32]	[27]
Propiomazine	DMKY8V1	Minor	Decreased absorption of Sucralfate due to adsorption of Propiomazine.	Insomnia [7A00-7A0Z]	[15]
Ibandronate	DM0QZBN	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Ibandronate.	Low bone mass disorder [FB83]	[28]
Propranolol	DM79NTF	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Propranolol.	Migraine [8A80]	[18]
Exjade	DMHPRWG	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Exjade.	Mineral absorption/transport disorder [5C64]	[29]
Prochlorperazine	DM53SRA	Minor	Decreased absorption of Sucralfate due to adsorption of Prochlorperazine.	Nausea/vomiting [MD90]	[15]
Promethazine	DM6I5GR	Minor	Decreased absorption of Sucralfate due to adsorption of Promethazine.	Nausea/vomiting [MD90]	[15]
Thiethylperazine	DMU3IET	Minor	Decreased absorption of Sucralfate due to adsorption of Thiethylperazine.	Nausea/vomiting [MD90]	[15]
Diclofenac	DMPIHLS	Minor	Altered absorption of Sucralfate caused by Diclofenac.	Osteoarthritis [FA00-FA05]	[30]
Naproxen	DMZ5RGV	Minor	Decreased absorption of Sucralfate due to formation of complexes caused by Naproxen.	Osteoarthritis [FA00-FA05]	[31]
Diflunisal	DM7EN8I	Minor	Altered absorption of Sucralfate caused by Diflunisal.	Pain [MG30-MG3Z]	[18]
Levomepromazine	DMIKFEL	Minor	Decreased absorption of Sucralfate due to adsorption of Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Fluphenazine	DMIT8LX	Minor	Decreased absorption of Sucralfate due to adsorption of Fluphenazine.	Psychotic disorder [6A20-6A25]	[15]
Triflupromazine	DMKFQJP	Minor	Decreased absorption of Sucralfate due to adsorption of Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Gatifloxacin	DMSL679	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[16]
Penicillamine	DM40EF6	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Penicillamine.	Rheumatoid arthritis [FA20]	[32]
Mesoridazine	DM2ZGAN	Minor	Decreased absorption of Sucralfate due to adsorption of Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Minor	Decreased absorption of Sucralfate due to adsorption of Thioridazine.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Minor	Decreased absorption of Sucralfate due to adsorption of Perphenazine.	Schizophrenia [6A20]	[15]
Chlorpromazine	DMBGZI3	Minor	Decreased absorption of Sucralfate due to adsorption of Chlorpromazine.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Minor	Decreased absorption of Sucralfate due to adsorption of Trifluoperazine.	Schizophrenia [6A20]	[15]
Cholic acid	DM7OKQV	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Cholic acid.	Synthesis disorder [5C52-5C59]	[33]
Deferiprone	DMS2M7O	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Deferiprone.	Thalassaemia [3A50]	[26]
Cinoxacin	DM4EWNS	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Cinoxacin.	Urinary tract infection [GC08]	[16]
Nalidixic acid	DMRM0JV	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Nalidixic acid.	Urinary tract infection [GC08]	[34]
Enoxacin	DMYTE6L	Moderate	Decreased absorption of Sucralfate due to formation of complexes caused by Enoxacin.	Urinary tract infection [GC08]	[16]
Methdilazine	DMAUHQX	Minor	Decreased absorption of Sucralfate due to adsorption of Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Minor	Decreased absorption of Sucralfate due to adsorption of Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[15]
-----------


⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sucralfate 1000 mg tablet	1000 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7055).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	ClinicalTrials.gov (NCT01284647) A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis. U.S. National Institutes of Health.
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
6	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
7	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
11	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
12	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
13	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
14	Cerner Multum, Inc. "Canadian Product Information.".
15	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
16	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
17	Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
18	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
19	Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624]
22	Carver PL, Berardi RR, Knapp MJ, Rider JM, Kauffman CA, Bradley SF, Atassi M "In vivo interaction of ketoconazole and sucralfate in healthy volunteers." Antimicrob Agents Chemother 38 (1994): 326-9. [PMID: 7910724]
23	Hava M, Hurwitz A "The relaxing effect of aluminum and lanthanum on rat and human gastric smooth muscle in vitro." Eur J Pharmacol 156 (1973): 156-61. [PMID: 4715218]
24	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
25	Havrankova J, Lahaie R "Levothyroxine binding by sucralfate." Ann Intern Med 117 (1992): 445-6. [PMID: 1503346]
26	Cerner Multum, Inc. "Australian Product Information.".
27	Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
28	Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
29	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
30	Pedrazzoli Junior J, Pierossi M de A, Muscara MN, Dias HF, da Silva CM, Mendes FD, de Nucci G "Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers." Br J Clin Pharmacol 43 (1997): 104-8. [PMID: 9056060]
31	Canadian Pharmacists Association.
32	Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
33	Product Information. Cholbam (cholic acid). Manchester Pharmaceutical, Fort Collins, CO.
34	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.